title: Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years.
abstract: OBJECTIVE
  To compare tumor recurrence, progression, and patient survival in T1G3 bladder tumors treated with transurethral resection (TUR) alone, early cystectomy, or TUR with an adjuvant 6-week course of bacille Calmette-Guérin (BCG) and followed up for a minimum of 5 years.
  
  
  METHODS
  Between 1979 and 1996, 94 patients with T1G3 bladder tumors (lamina propria invasion) were treated at nine different centers. The time to tumor recurrence, tumor stage and grade progression, number of delayed cystectomies, and patient survival were analyzed retrospectively in relation to the initial treatment.
  
  
  RESULTS
  The mean follow-up was 62 months. Thirty patients were treated by TUR alone (32%), 50 patients by TUR plus BCG (53%), and 14 patients by primary cystectomy (15%). The recurrence, progression, and cystectomy rates were significantly different between patients treated by TUR alone and TUR plus BCG (Fisher's exact test, P = 0.0005, P = 0.02, and P = 0.005, respectively). The disease-free survival was also significantly different when comparing TUR plus BCG with TUR alone or primary cystectomy (Kaplan-Meier analysis, log-rank test, P = 0.02).
  
  
  CONCLUSIONS
  Endoscopic resection plus BCG treatment of pT1G3 tumors allows an 80% rate of disease-free 5-year survival with bladder preservation. This conservative option has been widely accepted as first-line treatment, offering good cancer control with excellent quality of life. Very accurate surgical and pathologic evaluations before treatment and lifelong follow-up are obviously required.
authors.affiliation: Department of Urology, Centre Hospitalo-Universitaire Rennes, Rennes, France.
authors.forename: J
authors.initials: J
authors.lastname: Patard
authors.forename: S
authors.initials: S
authors.lastname: Moudouni
authors.forename: F
authors.initials: F
authors.lastname: Saint
authors.forename: N
authors.initials: N
authors.lastname: Rioux-Leclercq
authors.forename: A
authors.initials: A
authors.lastname: Manunta
authors.forename: L
authors.initials: L
authors.lastname: Guy
authors.forename: P
authors.initials: P
authors.lastname: Ballanger
authors.forename: Y
authors.initials: Y
authors.lastname: Lanson
authors.forename: M
authors.initials: M
authors.lastname: Hajri
authors.forename: J
authors.initials: J
authors.lastname: Irani
authors.forename: F
authors.initials: F
authors.lastname: Guillé
authors.forename: D
authors.initials: D
authors.lastname: Beurton
authors.forename: B
authors.initials: B
authors.lastname: Lobel
mesh_terms: D000368:Aged; D001500:BCG Vaccine; D003131:Combined Modality Therapy; D015653:Cystectomy; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine